October 20, 2015
Kowa has filed a new drug application in Japan for pemafibrate (development code: K-877), which was developed as a successor to its mainstay hypercholesterolemia medicine Livalo (pitavastatin), for the treatment of hyperlipidemia. The filing was made in Japan ahead of...read more